Massive Bio’s scientific advisory board provides subject matter expertise as it relates to the current treatment practices for cancer and how they may be evolving. Our board evaluates:
- Current treatment decisions on the selection of chemotherapy, backbones/biologics, and the sequencing of therapies based on recent data from world scientific meetings (ASCO, ESMO, AACR, etc.)
- Patient selection and approach towards personalized treatment with respect to tumor profiling and biomarker assessment.
- Economic analyses of cancer and how real world data (RWD) studies looking at effectiveness and costs would factor into treatment paradigms.
- The role of immunotherapy checkpoint inhibitors in cancer and other immune-oncology approaches in development.
Maurie is a nationally renowned oncologist and has more than 20 years of experience in cancer treatment and gynecologic research at some of the country's most recognized facilities, including MD Anderson Cancer Center, the Cleveland Clinic and Memorial Sloan-Kettering Cancer Center. In June 2011, he received the esteemed American Society of Clinical Oncology (ASCO) Statesman Award. Presented annually, the Statesman Award recognizes individual ASCO members who have shown extraordinary volunteer service, dedication and commitment to ASCO, their hospital community and the patients they serve for at least 20 years. Dedicated to finding new and innovative ways to treat cancer, Dr. Markman has published more than 1400 articles, editorials, peer-reviewed manuscripts, book chapters, reviews, letters and abstracts. He has also written or co-edited 10 books and served as an editorial board member on over 40 journals. He is currently Editor-in-Chief of numerous oncology journals, including Oncology Digest and Current Oncology Reports. He is also a Fellow of the American College of Physicians and the American Society of Clinical Oncology. Dr. Markman is regularly listed as one of the “Best Doctors in America” by Best Doctors, Inc., one of “America’s Top Doctors” by Castle Connelly Medical Ltd., and one of “America’s Top Oncologists” by Consumer’s Research Council of America. In 1999 he was recognized as the Lee and Jerome Burkons Research Chair in Oncology by the Cleveland Clinic.
Stefan leads early stage development of solid tumors and immuno-oncology in one of the largest the pharmaceutical companies. Stefan was the Sylvester Professor at the Miller School of Medicine at the University of Miami in Florida. From 2003–2008, he was the Clinical Director of the Braman Family Breast Cancer Institute. Before his move to Miami, Dr. Glück was Director, Southern Alberta Breast Cancer Program at the Tom Baker Cancer Center, and a Professor in the departments of oncology, medicine, pharmacology and therapeutics at the University of Calgary in Alberta, Canada, and Deputy Head, Department of Oncology at the University of Calgary. Dr. Glück was presented the America’s Top Oncologists award from Consumers’ Research Council of America. He was also recognized as one of the Best Doctors in America from 2006 through 2012. He has authored or co-authored more than 200 articles. In addition, Dr Glück has written or co-written a number of book chapters and numerous journal abstracts, and he has presented more than 350 papers at national and international meetings.
Edgardo practices at the Center for Hematology-Oncology (CHO) and is an Associate Professor of Clinical Biomedical Sciences at Florida Atlantic University, and Vice Chairman of the FLASCO Membership Committee. He earned his M.D. in 1994 at the University of Panama, School of Medicine, Republic of Panama. Dr. Santos completed his internship and residency training in Internal Medicine at Jackson Memorial Medical Center, University of Miami School of Medicine, Miami, Florida. Then, he went on to complete his fellowship in Hematology/Oncology at the Sylvester Comprehensive Cancer Center, Miami, Florida. Dr. Santos has authored or co-authored several manuscripts in peer-reviewed journals and also serves as reviewer for several scientific publications. Dr. Santos is a member of the Editorial Board of Expert Review series, Recent Patents on Biomarkers, and Clinical Practice. He has lectured mostly on topics related to lung and head and neck cancers as well as lymphoproliferative disorders and multiple myeloma. Dr. Santos’ main interests are the conduction and development of early phases of clinical trials. Furthermore, he has recently been selected by The International Association of HealthCare Professionals (IAHCP) to be published in the premier publication of The Leading Physicians of the World.